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INTRODUCTION: Despite improvement in clinical treatment for HIV-infected patients, the impact of antiretroviral therapy on 
the overall quality of life has become a major concern. 
OBJECTIVE: To identify factors associated with increased levels of self-reported quality of life among HIV-infected patients 
after four months of antiretroviral therapy. 
METHODS: Patients were recruited at two public health referral centers for AIDS, Belo Horizonte, Brazil, for a prospective ad-
herence study. Patients were interviewed before initiating treatment (baseline) and after one and four months. Quality of life was 
assessed using a psychometric instrument, and factors associated with good/very good quality of life four months after the initiation 
of antiretroviral therapy were assessed using a cross-sectional approach. Logistic regression was used for analysis. 
RESULTS: Overall quality of life was classified as ‘very good/good’ by 66.4% of the participants four months after initiating treat-
ment, while 33.6% classified it as ‘neither poor nor good/poor/very poor’. Logistic regression indicated that >8 years of education, 
none/mild symptoms of anxiety and depression, no antiretroviral switch, lower number of adverse reactions and better quality of 
life at baseline were independently associated with good/very good quality of life over four months of treatment. 
CONCLUSIONS: Our results highlight the importance of modifiable factors such as psychiatric symptoms and treatment-related 
variables that may contribute to a better quality of life among patients initiating treatment. Considering that poor quality of life is 
related to non-adherence to antiretroviral therapy, careful clinical monitoring of these factors may contribute to ensuring the long-
term effectiveness of antiretroviral regimens. 
KEYWORDS: Antiretroviral therapy; Anxiety; Depression; Adverse reactions; Antiretroviral therapy switch.
INTRODUCTION
The development of combined antiretroviral therapy has 
shifted the perception of HIV/AIDS from a fatal to a chronic 
and potentially manageable disease. Antiretroviral therapy 
is capable of improving survival, reducing the occurrence of 
HIV-related opportunistic infections and improving the patients’ 
quality of life (QL).1 Clinical improvement of HIV-infected 
patients under antiretroviral therapy (ART) has often been 
measured by reduction in mortality, opportunistic infection 
rates or severe AIDS-related symptoms.2 However, overall 
assessments of quality of life among people living with HIV/
AIDS have also become a major focus of interest as more 
efficacious and simpler regimen treatments are available. 
ART is highly effective and has the ability to bring significant 
benefits, which, despite unpleasant side effects and interference 
with daily activities and social routine, have a positive global 
outcome with regard to quality of life and general health.3
Several factors associated with better quality of life among 
HIV-infected patients have been reported in international 
literature. Sociodemographic characteristics such as male 
gender4, younger age,5 higher socioeconomic status6 and 868
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employment6 have been associated with improvement in QL. 
Other variables such as lower HIV viral load7, greater CD4+ 
cell count,5,7,8 fewer or less bothersome HIV symptoms,9 
and higher levels of hemoglobin10 have been shown to be 
important clinical/immunological indicators of better quality 
of life. In addition, patients with no difficulty in taking 
medications,5 those using regimens with a lower number 
of pills,5 and those more adherent to ART4,6,7 tend to have 
improved quality of life following the start of treatment. 
Moreover, the association between a better quality of life 
and the absence of psychiatric disorders and symptoms among 
people living with HIV/AIDS has been documented in several 
studies. Ruiz-Pérez et al. (2005) indicated that the absence 
of probable psychiatric disorders was associated with better 
scores in both physical health and mental health domains of 
health-related quality of life as measured by the MOS-HIV 
(Medical Outcomes Study HIV Health Survey). Murdaugh et 
al. (2006) indicated that HIV-infected women who reported 
fewer depressive symptoms had higher quality of life scores.
Despite the wide variety of instruments available to 
measure quality of life, there is no clear worldwide standard 
definition  12. According to the World Health Organization 
Quality of Life Group (WHOQOL Group), quality of life 
can be defined as “the individuals’ perception of their 
position in the context of the culture and value systems in 
which they live and in relation to their goals, expectations, 
standards and concerns”.13 
There are few studies of quality of life among people 
living with HIV/AIDS in developing countries,14 including 
Brazil.15,16 In addition, no prospective studies have evaluated 
the impact of antiretroviral therapy on the quality of life 
of ART-naive patients following treatment initiation in the 
Brazilian context of universal access to ART and specialized 
care for HIV/AIDS. In addition, ART is capable of providing 
an important impact on patient quality of life even during 
the first months of treatment. According to Mannheimer 
et al. (2005), significant improvements in mean quality of 
life were seen for HIV patients enrolled at two multi-center 
antiretroviral clinical trials after one and four months on new 
ART regimens; these improvements persisted for 12 months. 
Thus, the aim of this study was to identify factors associated 
with better levels of self-reported quality of life after four 
months of ART among HIV infected patients initiating 
treatment at two public health referral centers for HIV/AIDS 
in Belo Horizonte, Brazil.
MATERIALS AND METHODS
Participants
This analysis is part of the ATAR project, which was 
carried out in two AIDS public referral centers in Belo 
Horizonte (Brazil) from 2001 through 2003. The main 
objective of the study was to determine the incidence and 
determinants of non-adherence to antiretroviral therapy 
among HIV-infected patients who had initiated treatment.17 
The ATAR project included one baseline interview on the 
same day that patients received their first prescription for 
ART and three follow-up interviews at the first, fourth 
and seventh month thereafter (follow-up visits one, two 
and three, respectively). The baseline interview assessed 
sociodemographic, treatment-related and behavioral 
characteristics, while follow-up visits evaluated adherence 
and other treatment-related variables including ART switch, 
degree of difficulty and adverse reactions related to ART. 
Quality of life and symptoms of anxiety and depression 
were assessed at baseline and at the second follow-up visit 
(i.e., four months after the start of antiretroviral therapy). 
Additionally, clinical variables (e.g., clinical classification 
of AIDS, CD4+ cell count, viral load for HIV, and exposure 
category for HIV infection) were collected from medical 
charts. Participants signed a written informed consent and 
ethical approval was obtained from the Ethical Committee 
Board of both participating centers and from the Federal 
University of Minas Gerais.
Recruitment occurred at the main public referral centers 
for HIV/AIDS in the city: Infectious and Parasitic Diseases 
Training and Reference Center from the City Health 
Department, and Eduardo de Menezes Hospital, from the 
State Health Department. Participants who were at least 18 
years old and antiretroviral-naive were invited to participate 
in our study when they visited the centers for their first 
ART. Participants were assessed soon after receiving their 
first antiretroviral drugs from the pharmacy at each of the 
centers (baseline interview) and in the follow-up visits. For 
this analysis, only those who completed the quality of life 
assessment at baseline and at the second follow-up visit 
were included. Pregnant women were excluded from this 
analysis since most were taking antiretroviral medications 
for only a limited amount of time to prevent mother-to-child 
transmission. 
Event and exposure measurements
Quality of life
Quality of life was evaluated using the brief version of 
the World Health Organization Quality of Life instrument 
(WHOQOL-bref), a 26-item generic instrument derived 
from the complete WHOQOL-100 version.18 This scale 
has been validated in many countries, including Brazil, and 
has adequate psychometric characteristics such as internal 
consistency, discriminating validity and reliability.13,18869
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We used the overall perception of quality of life as the 
outcome measurement in a cross-sectional analysis approach 
during visit two, which occurred at approximately four 
months after treatment initiation. Assessment was performed 
by asking patients to classify their quality of life as ‘very 
poor’, ‘poor’, ‘neither poor nor good’, ‘good’ and ‘very 
good’. This single item approach has been suggested to be a 
good indicator of self-reported quality of life.19
Exposure variables
Exposure variables for this analysis were chosen by 
considering the conceptual framework for quality of life 
in HIV/AIDS proposed by Vidrine et al. (2005), which 
suggests that health outcomes fall along a continuum that 
begins with biological/physiological variables, is followed 
by symptoms and measures of functional abilities, and 
ends with general health perceptions and overall quality 
of life. In addition, the framework suggests that behavioral 
factors and socioeconomic status have significant effects 
on this continuum and should be carefully examined when 
evaluating quality of life data among HIV-infected patients. 
Thus, we included sociodemographic characteristics (e.g., 
sex, age, skin color), clinical variables (e.g., time since 
diagnosis, AIDS clinical classification, late ART initiation, 
and symptoms of anxiety and depression), behavioral data 
(e.g., exposure category for HIV infection and alcohol use), 
measures of functional abilities (perceived improvement for 
ten specific items evaluating health status), treatment-related 
factors (use of protease inhibitors, self-reported degree of 
difficulty related to ART, self-reported adverse reactions 
related to ART, adherence to ART), and overall quality 
of life at baseline as explanatory variables. We collected 
information on the antiretroviral regimen prescribed for each 
patient. This variable was then dichotomized and patients 
were classified based on the use of at least one protease 
inhibitor (PI) drug plus nucleoside/nucleotide analog reverse 
transcriptase inhibitors and non-nucleoside analog reverse 
transcriptase inhibitors, or only nucleoside/nucleotide 
analog reverse transcriptase inhibitors combined with non-
nucleoside analog reverse transcriptase inhibitors. The skin 
color was a self-reported characteristic. Late ART initiation 
was defined as a CD4+ T cell count under 200 cells/mm3 or 
any AIDS defining condition (CDC clinical classification 
“C”) at baseline, as recorded in the medical record. AIDS 
clinical classification was defined according to the Centers 
for Disease Control and Prevention (1992).21 Time since 
diagnosis was defined as the time interval between the HIV 
test result and the first prescription for ART. 
Anxiety and depression symptoms were assessed using 
the Hospital Anxiety and Depression Scale (HADS).22 
HADS has been validated in many countries, including 
Brazil23, and it has been applied to non-psychiatric patients. 
Participants were classified regarding the level of symptoms 
of anxiety and depression according to Zigmond and Snaith 
(1983). Scores over 14 were considered as severe anxiety/
depression, 11-14 as moderate, 8-10 as mild or “subclinical” 
and under 8 as absence of symptoms of anxiety/depression. 
Anxiety and depression scores were analyzed separately and 
both were categorized as dichotomous variables, comparing 
participants with lack of or mild symptoms to those with 
moderate or severe symptoms. 
During the second visit, patients were asked to report 
whether they had had any improvement in ten specific items 
related to their health status including energy, pain/physical 
discomfort, dependence on other people, ability to walk, 
ability to work, memory/ability to concentrate, physical 
appearance, self-esteem, personal relationships and sexual 
life. Each item was considered separately in our analysis.
Adverse reactions related to ART were self-reported. 
We collected information on gastrointestinal, neurological 
and dermatological issues in addition to anemia, fatigue, 
fever and other freely reported reactions. Patients were 
specifically asked if they had experienced each of these. We 
used the mean value of adverse reactions reported at visit 
two (mean = 2) to categorize this variable. Similarly, self-
reported degree of difficulty related to antiretroviral therapy 
was categorized as a dichotomous variable; this allowed us 
to compare participants who classified their treatment as 
having ‘low and very low difficulty’ to those who described 
it as having ‘medium, high and very high difficulty’ at visit 
two, at the four month mark. Finally, adherence to ART was 
defined as taking at least 95% of all prescribed doses in the 
last three days prior to the visit two follow-up, based on 
evidence that optimal virologic success declines rapidly in 
patients taking fewer than 95% of their prescribed doses.24 
Data analysis
For analysis purposes, we dichotomized the outcome 
variable (i.e., overall perception of quality of life), 
comparing ‘neither poor nor good, poor and very poor’ 
quality of life to ‘good and very good’ quality of life, due 
to power considerations. The chi-square test was used 
for analysis of categorical data. The magnitude of the 
associations was estimated by the odds ratio (OR) with 
95% confidence interval (95% CI). The level of significance 
considered was 0.05. Quality of life at baseline and at visit 
two were compared using McNemar’s test. The independent 
association between potential explanatory variables and 
better quality of life at visit two was assessed by multivariate 
analysis using logistic regression. Variables statistically 
associated with good or very good quality of life in the 870
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univariate analysis (p-value less than .20) were considered 
for modeling. Sequential deletion was conducted until a final 
model was obtained that included only variables showing 
statistical significance at a p-value under .05. The Wald test 
was used to assess the importance of each variable and the 
likelihood ratio test was used to compare models. Adequacy 
of the final model was evaluated using the Hosmer-
Lemeshow test.25
RESULTS
Descriptive characteristics
Among the 406 participants recruited for the ATAR 
project, 314 (77.3%) returned for the second follow-up visit 
and 297 (73.2%) completed the WHOQOL-bref during 
both baseline and second visits. After excluding 35 women 
on ART because of pregnancy, 262 (64.5%) individuals 
were eligible for this analysis. No statistically significant 
difference was observed between participants and non-
participants or those lost to follow-up regarding age, sex or 
site of medical assistance. Median time between baseline 
and the second visit was 122 days. During the second visit, 
16.4% and 50.0% classified their quality of life as ‘very 
good’ and ‘good’, respectively, while 24.5% classified their 
quality of life as ‘neither poor nor good’, 5.3% as ‘poor’ and 
3.8% as ‘very poor’. We observed a statistically significant 
improvement in the perception of quality of life when 
comparing the baseline with the second visit assessments. 
One hundred fifty-four (58.8%) and 108 (41.2%) patients 
considered their quality of life ‘good/very good’ and ‘neither 
poor nor good/poor/very poor’ at baseline as compared to the 
proportions reported at the second visit (66.4% and 33.6%, 
respectively) (McNemar’s test=4.88; p-value=0.027). 
Most participants were male (66.0%), less than 35 years 
old (53.0%), and single, divorced or widowed (64.1%). Half 
had little schooling (< 8 years), and 33.9% had a family 
income of one minimum wage (US$ 80) or no income 
at all in the last month prior to the baseline interview. 
Approximately 20.0% of the participants were living alone, 
while 11.8% and 68.3% were living with a partner or 
other people including children, relatives and friends. The 
proportion of better quality of life was higher among men 
and participants with a family income in the last month that 
was greater than one minimum wage (Table 1).
For most participants, the length of time between HIV 
diagnosis and the first antiretroviral prescription was greater 
than 90 days (57.3%). At the baseline interview, 53.8% 
were symptomatic or presented at least one AIDS-defining 
condition, 42.0% had LTCD4 counts < 200 cells/mm3, 
and the median HIV viral load was 124,000 copies/mL. 
However, due to the high proportion of missing values for 
HIV viral load (54.5%), this variable was not considered for 
further analysis. Also, the percentage of patients initiating 
antiretroviral therapy with a low CD4+ cell count or 
advanced disease (66.7%) was remarkably high. 
There was a higher proportion of participants that 
reported lack of or mild symptoms of anxiety (80.9%) and 
depression (84.7%) at the second visit as compared to the 
frequency of none/mild anxiety and depression symptoms at 
baseline (63.0% and 78.6%, respectively) (data not shown). 
Of these patients, only 11.8% reported the use of anxiolytic 
and/or antidepressive medications during the follow-up 
period. Most reported not using injected drugs during their 
lifetime (93.9%) or alcohol in the last month prior to the 
baseline interview (63.4%).
Following the initiation of ART, participants reported 
some improvement regarding health status including 
energy (51.1%), self-esteem (40.8%), physical appearance 
(40.4%), pain/physical discomfort (37.0%), ability to work 
(35.9%), ability to walk (31.7%), memory (29.0%), personal 
relationships (28.2%), and dependence on other people 
(27.5%), but only 14.9% reported improvement in their sex 
life. 
Approximately half of the participants initiated ART with 
a regimen containing protease inhibitors, with 44.3% taking 
less than eight pills of antiretroviral drugs per day, and 
79.4% remained on the same antiretroviral regimen during 
the follow-up period. 
Four months after initiating ART, 58.5% of the 
individuals classified their treatment as easy or very easy, 
88.9% reported two or less adverse reactions related to ART, 
and a high proportion (79.0%) were adherent to treatment.
Univariate analysis
Among the sociodemographic variables, a statistically 
significant association was observed between male sex, eight 
or more years of formal education, family income in the 
last month equal to or under one minimum wage (US$80) 
or greater than one minimum wage and a better quality of 
life (good/very good) (Table 1). Participants with lack of or 
mild symptoms of anxiety and depression and those who 
reported not using injected drugs during their lifetime had 
a greater chance of classifying their quality of life as good/
very good at the second visit. In addition, the perception 
of improvement in overall energy, ability to walk, ability 
to concentrate, physical appearance, self-esteem, personal 
relationships and sexual life were associated with better 
quality of life. Also, maintaining same antiretroviral regimen 
during the follow-up period, perception of the degree of 
difficulty related to ART as easy or very easy, having a lower 871
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Table 1 - Univariate analysis of factors associated with good or very good quality of life (QL) at month 4 among participants 
(n=262), ATAR Project, Brazil, 2001-2003
Characteristics QL good/very good
p-value
OR (95% CI)
Sociodemographics
1. Center (HEM) 0.74 (0.39-1.39) 0.343
2. Male sex 1.70 (0.99-2.90) 0.049
3. Age ≤ 35 years old 0.91 (0.55-1.53) 0.731
4. Skin color (white) 0.97 (0.54-1.75) 0.920
5. Marital status (single, divorced or widowed) 1.28 (0.76-2.19) 0.350
6. Education (≥ 8 years) 2.48 (1.46-4.22) 0.001
7. Family income in the last month:
  None 
  ≤ 1 MW a
  > 1 MW 
1.00
0.51 (0.26-0.98)
1.96 (1.16-3.31)
0.041
0.011
8. Housing partnership:
  Living with partner
  Living with others
  Living alone
1.00
1.38 (0.80-2.37)
0.94 (0.50-1.79)
0.246
0.861
Clinical
9. Time since diagnosis (days):
  ≤ 30
  31 - 90
  > 90
1.00
1.56 (0.89-2.76)
0.78 (0.46-1.31)
0.121
0.338
10. No late ART initiation (CD4 < 200 cells/mm3 or any AIDS defining condition at baseline) 0.97 (0.55-1.72) 0.922
11. Symptoms of anxiety at visit two (none/mild) 10.26 (4.98-21.12) <0.001
12. Symptoms of depression at visit two (none/mild) 11.86 (5.16-27.24) <0.001
Behavioral
13. Injection drug use in lifetime (no) 2.72 (0.98-7.56) 0.047
14. Alcohol use in the prior month to baseline (no) 0.98 (0.58-1.67) 0.947
Functional abilities
15. Perceived improvement of energy at visit two (yes) 1.87 (1.11-3.16) 0.018
16. Perceived improvement of pain/physical discomfort at visit two (yes) 1.41 (0.82-2.43) 0.213
17. Perceived improvement of dependence on other people at visit two (yes) 1.10 (0.62-1.98) 0.728
18. Perceived improvement of the ability to walk at visit two (yes) 1.94 (1.07-3.48) 0.026
19. Perceived improvement of the ability to work at visit two (yes) 1.66 (0.95-2.90) 0.072
20. Perceived improvement of memory/ability to concentrate at visit two (yes) 2.38 (1.27-4.45) 0.006
21. Perceived improvement of physical appearance at visit two (yes) 2.04 (1.18-3.53) 0.010
22. Perceived improvement of self-esteem at visit two (yes) 2.09 (1.21-3.61) 0.008
23. Perceived improvement of personal relationships at visit two (yes) 2.26 (1.20-4.23) 0.010
24. Perceived improvement of sexual life at visit two (yes) 2.60 (1.10-6.17) 0.025
Treatment-related behaviors
25. Use of other medications during follow-up period:
  None
  Others 
  Anxiolytic/antidepressive meds
1.00
1.29 (0.77-2.16)
0.67 (0.31-1.43)
0.328
0.295
26. Use of protease inhibitor (no) 1.07 (0.64-1.79) 0.792
27. ART switch during follow-up period (no) 2.66 (1.44-4.90) 0.001
28. Daily number of antiretroviral pills (< 8) 1.07 (0.64-1.79) 0.800
29. Self-reported degree of difficulty related to ART at visit two (easy, very easy) 2.02 (1.20-3.42) 0.008
30. Self-reported adverse reactions (AR) related to ART at visit two (≤2) 3.81 (1.71-8.49) 0.001
31. Self-reported adherence to ART at visit two (adherent) 2.10 (1.14-3.85) 0.016
32. Overall quality of life at baseline (good/very good) 4.43 (2.57-7.65) <0.001
a Minimum Wage (US$80)872
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number of adverse reactions, and being adherent to therapy 
were all associated with better quality of life at the second 
visit. Finally, participants who classified their quality of 
life as good or very good at baseline had a greater chance 
of reporting good or very good quality of life at the second 
visit.
Multivariate analysis
Logistic regression indicated that eight or more years 
of formal education (OR=2.05; 95% CI=1.07-3.92), non-
occurrence or presence of mild symptoms of anxiety 
(OR=4.31; 95% CI=1.84-10.12) and depression (OR=4.91; 
95% CI=1.85-12.98), maintaining the same antiretroviral 
regimen during the follow-up period (OR=2.08; 95% 
CI=1.00-4.34), having a lower number of adverse reactions 
(OR=3.52; 95% CI=1.30-9.50) and reporting better quality 
of life at baseline (OR=3.40; 95% CI=1.79-6.44) were 
independently associated with good/very good quality of life 
over four months of treatment (Table 2).
DISCUSSION
By using a single facet of the WHOQOL-bref instrument, 
we were able to assess the patients’ quality of life four 
months after initiating ART (visit two), based on the 
individuals’ perceptions, values and preferences. This 
instrument could be easily applied to a health service 
scenario and would be an important tool for assessing 
patients’ quality of life at the onset of treatment and over the 
course of treatment. The WHOQOL-bref has the advantage 
of including a broader, multidimensional concept of quality 
of life, and providing a global measure of quality of life in 
a single item12. Although we were not able to assess quality 
of life data longitudinally over the treatment course in 
more than one follow-up visit, we found a high proportion 
of patients who reported good or very good quality of life 
after approximately four months of ART (66.4%) and a 
statistically significant difference when comparing these 
results with the baseline assessment; this suggests an 
improvement of reported QL after initiating treatment. 
Similarly, Mannheimer et al. (2005) described a significant 
improvement of QL at the first, fourth and twelfth months 
in a sample of 1050 HIV-infected individuals receiving 
ART in two large multi-center antiretroviral clinical trials. 
By examining quality of life among ART-naive patients 
following treatment initiation, we were able to identify 
important variables associated with a better perception of 
quality of life based on the individual’s assessment.
Overall self-perception of quality of life has been shown 
to be a useful screening item for assessing global quality 
of life.12,19 Despite the difficulties in comparison with other 
studies due to methodological issues such as study design 
and population heterogeneity, many authors have used this 
item as an outcome variable for quality of life analyses in 
different settings. We found a lower proportion of good and 
very good quality of life as compared to individuals seeking 
primary care services in Porto Alegre, Brazil (73.3%).26 
Norekval et al. (2007) conducted two cross-sectional 
surveys to evaluate quality of life using the WHOQOL-bref 
on female myocardial infarction survivors and the general 
Norwegian population. The proportion of good and very 
good quality of life among female myocardial infarction 
survivors was similar to our findings (67%); however, a 
higher proportion of good and very good quality of life 
was found among the general population of that country 
(79%). Also, we found a higher proportion of good or very 
good quality of life as compared to individuals at various 
stages of their illness recruited at an HIV counseling clinic 
in Bangalore, India (18%).11 It is likely that favorable 
conditions of free and universal access to HIV/AIDS care 
and treatment in Brazil as compared to India during the same 
time period influenced this result.
Symptoms of anxiety and depression are important 
Table 2 - Adjusted model for multivariate analysis of good/very good quality of life at month 4 among participants (n=262), 
ATAR Project, Brazil, 2001-2003
Characteristics Good or very good QL at the 2nd visit a
OR (95% CI) p-value
Education >8 years 2.05 (1.07-3.92) 0.029
Lack of/mild symptoms of anxiety at visit two 4.31 (1.84-10.12) <0.001
Lack of/mild symptoms of depression at visit two 4.91 (1.85-12.98) 0.001
No ART switch during follow-up period 2.08 (1.00-4.34) 0.050
<2 adverse reactions related to ART at visit two  3.52 (1.30-9.50) 0.013
Good/very good quality of life at baseline 3.40 (1.79-6.44) <0.001
a Hosmer-Lemeshow Test: c2 = 0.918; degree of freedom; p-value= 0.969873
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factors related to quality of life since they may contribute 
to unfavorable HIV clinical course by worsening immune 
function28 or affecting the patient’s behavior,29 perception of 
the degree of difficulty with the treatment3,30 and adherence 
to treatment.31 The impact of psychiatric symptoms on 
the quality of life of patients with HIV/AIDS has been 
highlighted previously.15,32 More importantly, Chan et al. 
(2003) described a statistically significant reduction in 
psychiatric symptoms when comparing different treatment 
groups in a representative sample of HIV-infected patients 
receiving care in the United States, including patients 
receiving ART at baseline and follow-up, patients who 
initiated ART at baseline, patients who were on ART only 
at baseline and patients who were not on ART. Despite 
the cross-sectional nature of the current study, our results 
suggest a strong association between lack of and mild 
symptoms of anxiety and depression and a better quality of 
life. This suggests that patients experiencing moderate and 
severe symptoms of anxiety and depression could potentially 
benefit from appropriate intervention (i.e., counseling, 
diagnosis and pharmacological and non-pharmacological 
treatment). Therefore, we emphasize the importance of 
evaluating the occurrence of anxiety and depression among 
HIV-infected patients prior to initiating ART and during the 
treatment course as an important tool to potentially improve 
the quality of life and contribute to enhanced treatment effect 
via better adherence to ART. 
Treatment-related factors were found to be barriers to 
a good quality of life. This is consistent with the literature, 
which indicates that maintaining the same antiretroviral 
regimen during the follow-up period and a having a lower 
number of adverse reactions secondary to the use of ART are 
related to a better quality of life.34,35 These results underline 
the importance of treatment-related variables as markers 
of post-treatment quality of life and the need to develop 
intervention strategies focused on symptoms related to ART 
and regimen switch along the treatment course. Accurate 
assessment and management of adverse reactions should 
be part of a comprehensive healthcare plan among patients 
with HIV/AIDS, thus optimizing patients’ satisfaction with 
treatment and their adherence. 
Education, a proxy of socioeconomic status, has also 
known been shown to influence quality of life. Our analysis 
showed that patients with higher education reported better 
quality of life, possibly due to better knowledge about 
their treatment and disease, access to health services or 
functional status.36,37 This result is similar to those from 
other studies among HIV/AIDS patients37 as well as among 
different populations, including a sample of men with 
prostate cancer38 and the general population in Sweden.39 
Less education in combination with the adverse and physical 
consequences of HIV/AIDS may be particularly detrimental 
to quality of life outcomes.
Previous studies have suggested that a better perception 
of quality of life at baseline is a strong predictor of better 
quality of life after initiating ART,8,35 a potential carry-
over effect during the course of treatment. Also, patients 
with worse quality of life at baseline could have higher 
proportions of anxiety and depression symptoms as well as 
a worse clinical condition for AIDS; this could negatively 
affect quality of life at follow-up, independent of adherence 
to ART. Because baseline values may influence future 
levels of quality of life,35 multivariate analysis should take 
into account the quality of life perception at baseline. This 
association was confirmed in our findings. However, given 
our cross-sectional approach, the independent association 
between baseline assessment of quality of life and good/
very good quality of life at month four should be interpreted 
with caution.
Although we did not find a statistical association between 
adherence to ART and good or very good quality of life 
in the multivariate analysis, other authors have described 
this association.4,7 According to Mannheimer et al. (2005), 
participants reporting 100% ART adherence achieved 
significantly higher quality of life scores at 12 months of 
follow-up as compared to those with poorer adherence, 
particularly when 100% adherence was sustained (at months 
1, 4, 8 and 12) (p</0.001). The short period of observation 
between the two visits in our study and lack of statistical 
power could partially explain our findings. Although other 
authors have described an association between better quality 
of life and male gender4 and higher family income6, this is 
not consistent in the literature.
This study reports a significant improvement in overall 
quality of life four months after initiation of ART for 
patients receiving antiretroviral medications at two HIV/
AIDS referral centers in Brazil. Our results indicate that the 
patients could benefit from an easy and simple screening 
tool for perceived quality of life before and during the 
treatment course, as quality of life could be easily assessed 
in the health service scenario by using one single facet of the 
WHOQOL-bref. Clinical assessment of adverse reactions 
during the course of treatment and a careful monitoring 
after any antiretroviral switch could contribute to a better 
quality of life, improve the patient-physician relationship 
and potentially maintain adherence with fewer undesired 
side effects. Also, patients would benefit from an early and 
continuous assessment of psychiatric symptoms including 
early diagnosis of psychiatric disorders and implementation 
of specific pharmacological and non-pharmacological 
treatments such as counseling and psychotherapy. Because 
poor quality of life is associated with non-adherence4 and 874
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previous studies have suggested that anxiety, depression, 
and adverse reactions to ART and ART switch are strong 
predictors of non-adherence to ART,3,17 these strategies may 
also contribute to improvement of adherence to ART in these 
public settings. 
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